Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - ARCA biopharma, Inc. | abio-ex312_9.htm |
| EX-31.1 - EX-31.1 - ARCA biopharma, Inc. | abio-ex311_6.htm |
| EX-23.1 - EX-23.1 - ARCA biopharma, Inc. | abio-ex231_7.htm |
| EX-4.7 - EX-4.7 - ARCA biopharma, Inc. | abio-ex47_80.htm |
| 10-K - 10-K - ARCA biopharma, Inc. | abio-10k_20191231.htm |
Exhibit 32.1
ARCA BIOPHARMA, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. SEC. 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350), Michael R. Bristow, Chief Executive Officer of ARCA biopharma, Inc. (the “Company”), and Brian L. Selby, Vice President, Finance of the Company, each hereby certifies that, to the best of his knowledge:
|
|
(1) |
The Company’s Annual Report on Form 10-K for the period ended December 31, 2019, to which this Certification is attached as Exhibit 32.1 (the “Annual Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and |
|
|
(2) |
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
In Witness Whereof, the undersigned have set their hands hereto as of the 18th day of February, 2020.
|
/s/ Michael R. Bristow |
|
/s/ Brian L. Selby |
|
Michael R. Bristow |
|
Brian L. Selby |
|
President and Chief Executive Officer |
|
Vice President, Finance |
A signed original of this written statement required by Section 906 of the Public Company Accounting Reform and Investor Protection Act of 2002 (18 U.S.C. § 1350, as adopted) has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. This certification accompanies the Annual Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of ARCA biopharma, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Annual Report), irrespective of any general incorporation language contained in such filing.